Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis

Journal of Hepatology

Volumn 41, Issue 2, 2004, Pages 229-234

  Spahr, Laurent ^a   Giostra, Emile ^a   Frossard, Jean Louis ^a   Bresson Hadni, Solange ^a   Rubbia Brandt, Laura ^a   Hadengue, Antoine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Alcoholic hepatitis; CD14; Clinical study; Lipopolysaccharide binding protein; Maddrey's discriminant function; Mortality; Multivariate analysis; Soluble TNF receptor 1; sTNF R1, soluble TNF receptor 1; TNF

Indexed keywords

CD14 ANTIGEN; CYTOKINE; LIPOPOLYSACCHARIDE BINDING PROTEIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; ENDOTOXEMIA; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; INFLAMMATION; LIVER BIOPSY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ALCOHOL DRINKING; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REGRESSION ANALYSIS; ROC CURVE; SOLUBILITY; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4444220877     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.04.028     Document Type: Article

References (40)

1. McClain C.J., Barve S., Deaciuc I., Kugelmas M., Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 19:1999;205-219
2. Parlesak A., Schäfer C., Schütz T., Bode J.C., Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 32:2000;742-747
3. Fukui H., Brauner B., Bode J.C., Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol. 12:1991;162-169
4. Keshavarzian A., Holmes E.W., Patel M., Iber F., Fields J.Z., Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 94:1999;200-207
5. Tilg H., Wilmer A., Vogel W., Herold M., Nölchen B., Judmaier G., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 103:1992;264-274
6. Khoruts A., Stahnke L., McClain C.J., Logan G., Allen J.I. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 13:1991;267-276
7. McClain C.J., Barve S., Barve S., Deaciuc I., Hill D.B. Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res. 22:1998;248S-252S
8. Schäfer C., Parlesak A., Schütt C., Bode J.C., Bode C. Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability- increasing protein, soluble CD14 and plasma lipids in relation to endotoxemia in patients with alcoholic liver disease. Alcohol Alcohol. 37:2002;81-86
9. Uesugi T., Froh M., Arteel G.E., Bradford B.U., Wheeler M.D., Gäbele E., et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol. 168:2002;2963-2969
10. Albillos A., de la Hera A., Gonzalez M., Moya J.L., Calleja J.L., Monserrat J., et al. Increased lipolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 37:2003;208-217
11. Urbaschek R., McCuskey R.S., Rudi V., Becker K.P., Sticker F., Urbaschek B., et al. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res. 25:2001;261-268
12. Yin M., Bradford B.U., Wheeler M.D., Uesugi T., Froh M., Goyert S.M., et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol. 166:2001;4737-4742
13. Felver M.E., Mezey E., McGuire M., Mitchell M.C., Herlong H.F., Veech G.A., et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res. 14:1990;255-259
14. Rodriguez-Rodriguez E., Gonzalez-Reimers E., Santolaria-Fernandez F., Milena-Abril A., Rodriguez-Moreno F., Oramas-Rodriguez J., et al. Cytokine levels in acute alcoholic hepatitis: a sequential study. Drugs Alcohol Depend. 39:1995;23-27
15. Bird G.L.A., Sheron N., Goka J., Alexander G.J., Williams R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med. 112:1990;917-920
16. Spahr L., Rubbia-Brandt L., Frossard J.L., Giostra E., Rougemont A.L., Pugin J., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 37:2002;448-455
17. Tilg H., Jalan R., Kaser A., Davies N.A., Offner F.A., Hodges S.J., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 38:2003;419-425
18. Papadakis K.A., Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 119:2000;1148-1157
19. Bradham C.A., Plumpe J., Manns M.P., Brenner D.A., Trautwein C. Mechanisms of hepatic toxicity: TNF-induced liver injury. Am J Physiol. 275:1998;G387-G392
20. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., et al. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology. 117:1999;942-952
21. Beutler B., van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 264:1994;667-668
22. Leist M., Gantner F., Jilg S., Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol. 154:1995;1307-1316
23. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino M.A., Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA. 88:1991;9292-9296
24. Naveau S., Emilie D., Balian A., Grangeot-Keros L., Borotto E., Portier A., et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J Hepatol. 28:1998;778-784
25. Byl B., Roucloux I., Crusiaux A., Dupont E., Deviere J. Tumor necrosis factor α and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology. 104:1993;1492-1497
26. Simpson K.J., Lukacs N.W., Colletti L., Strieter R.M., Kunkel S.L. Cytokines and the liver. J Hepatol. 27:1997;1120-1132
27. Pessione F., Ramond M.J., Peters L., Pham B.N., Batel P., Rueff B., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 23:2003;45-53
28. Carithers R.L., Franklin Herlong H., Diehl A.M., Shaw E.W., Combes B., Fallon H.J., et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. Ann Intern Med. 110:1989;685-690
29. Mathurin P., Mendenhall C.L., Carithers R.L., Ramond M.J., Maddrey W.C., Garstide P., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 36:2002;480-487
30. International group. Alcoholic liver disease: morphological manifestations. Review by an International Group. Lancet. 1:1981;707-711
31. Bautista A.P. Neutrophilic infiltration in alcoholic hepatitis. Alcohol. 27:2002;17-21
32. Mathurin P., Abdelnour M., Ramond M.-J., Carbonell N., Fartoux L., Serfaty L., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 38:2003;1363-1369
33. Mutimer D.J., Burra P., Neuberger J.M., Hubscher S., Buckels J.A., Mayer A.D., et al. Managing severe alcoholic hepatitis complicated by renal failure. Q J Med. 86:1993;649-656
34. Fujimoto M., Uemura M., Kojima H., Ishii Y., Ann T., Sakurai S., et al. Prognostic factors in severe alcoholic liver injury. Nara Liver Study Group. Alcohol Clin Exp Res. 23:1999;33S-38S
35. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 7:1987;1346-1358. p. 649-56
36. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA. 89:1992;4845-4849
37. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 172:1990;599-607
38. Spinas G.A., Keller U., Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest. 90:1992;533-536
39. Fujimoto M., Uemura M., Nakatani Y., Tsujita S., Hoppo K., Tamagawa T., et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res. 24:2000;48S-54S
40. Reimold A.M. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci. 325:2003;75-92